HELIOS TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HELIOS TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jan 2, 2016 | $200.73M | Mar 1, 2016 |
| FY2015 | Dec 27, 2014 | $227.67M | Mar 1, 2016 |
| FY2013 | Dec 28, 2013 | $205.27M | Mar 7, 2014 |
| FY2013 | Dec 29, 2012 | $204.37M | Mar 7, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $839.00M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $805.90M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $835.60M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $885.40M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $869.20M | Feb 27, 2024 |
| FY2020 | Jan 2, 2021 | $151.62M | Mar 2, 2021 |
| FY2020 | Sep 26, 2020 | $122.65M | Mar 2, 2021 |
| FY2020 | Jun 27, 2020 | $119.29M | Mar 2, 2021 |
| FY2020 | Mar 28, 2020 | $129.48M | Mar 2, 2021 |
| FY2020 | Dec 28, 2019 | $125.93M | Mar 2, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $84.15M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $88.00M | Feb 27, 2018 |
| FY2017 | Jul 1, 2017 | $89.34M | Feb 27, 2018 |
| FY2017 | Apr 1, 2017 | $81.35M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $49.87M | Feb 27, 2018 |
| FY2017 | Oct 1, 2016 | $45.23M | Feb 27, 2018 |
| FY2017 | Jul 2, 2016 | $50.81M | Feb 27, 2018 |
| FY2017 | Apr 2, 2016 | $51.03M | Feb 27, 2018 |
| FY2016 | Jan 2, 2016 | $44.29M | Feb 28, 2017 |
| FY2016 | Sep 26, 2015 | $48.04M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $271.20M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $252.30M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $261.70M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $298.50M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $312.80M | Feb 27, 2024 |
| FY2020 | Jan 2, 2021 | $52.72M | Mar 2, 2021 |
| FY2020 | Sep 26, 2020 | $46.94M | Mar 2, 2021 |
| FY2020 | Jun 27, 2020 | $44.72M | Mar 2, 2021 |
| FY2020 | Mar 28, 2020 | $51.85M | Mar 2, 2021 |
| FY2020 | Dec 28, 2019 | $47.43M | Mar 2, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $48.40M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $39.00M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $37.50M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $98.40M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $104.60M | Feb 27, 2024 |
| FY2020 | Jan 2, 2021 | $5.55M | Mar 2, 2021 |
| FY2020 | Sep 26, 2020 | $12.98M | Mar 2, 2021 |
| FY2020 | Jun 27, 2020 | $12.91M | Mar 2, 2021 |
| FY2020 | Mar 28, 2020 | ($17.22M) | Mar 2, 2021 |
| FY2020 | Dec 28, 2019 | $13.81M | Mar 2, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $66.00M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $81.80M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $79.90M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $137.30M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $149.30M | Feb 27, 2024 |
| FY2020 | Jan 2, 2021 | $10.40M | Mar 2, 2021 |
| FY2020 | Sep 26, 2020 | $18.34M | Mar 2, 2021 |
| FY2020 | Jun 27, 2020 | $16.70M | Mar 2, 2021 |
| FY2020 | Mar 28, 2020 | ($10.03M) | Mar 2, 2021 |
| FY2020 | Dec 28, 2019 | $18.77M | Mar 2, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $19.10M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $20.10M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $19.20M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $17.40M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $16.80M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $15.60M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $15.16M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $14.12M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $10.62M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $4.33M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $147.60M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $139.00M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $148.90M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $133.10M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $130.70M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $106.80M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $99.67M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $93.87M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $65.58M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $35.35M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $127.30M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $122.10M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $83.90M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $109.90M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $113.10M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $108.60M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $90.48M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $77.45M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $49.38M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $38.51M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $23.70M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $27.00M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $34.30M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $31.90M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $26.80M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $14.60M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $25.03M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $28.38M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $22.21M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $6.19M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $1.51B | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $1.51B | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $1.59B | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $1.46B | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $1.42B | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $1.30B | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $1.02B | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $1.04B | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $459.77M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $444.78M | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $583.00M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $641.00M | Mar 3, 2026 |
| FY2024 | Dec 30, 2023 | $735.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $668.80M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | $706.30M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | $689.19M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $444.12M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $511.40M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $187.09M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $208.38M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $931.50M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $864.40M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $854.60M | Mar 3, 2026 |
| FY2026 | Dec 31, 2022 | $794.90M | Mar 3, 2026 |
| FY2024 | Jan 1, 2022 | $709.00M | Feb 25, 2025 |
| FY2023 | Jan 2, 2021 | $607.80M | Feb 27, 2024 |
| FY2022 | Dec 28, 2019 | $577.60M | Feb 28, 2023 |
| FY2021 | Dec 29, 2018 | $530.77M | Mar 1, 2022 |
| FY2020 | Dec 30, 2017 | $272.67M | Mar 2, 2021 |
| FY2019 | Dec 31, 2016 | $236.40M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $498.10M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $498.90M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $514.00M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $468.50M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $459.90M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $443.50M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $377.57M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $383.13M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $108.87M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $103.58M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $539.10M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $502.60M | Mar 3, 2026 |
| FY2024 | Dec 30, 2023 | $475.60M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $450.00M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | $363.30M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | $270.32M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $267.66M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $219.06M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $183.77M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $162.49M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $73.00M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $44.10M | Mar 3, 2026 |
| FY2024 | Dec 30, 2023 | $32.40M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $43.70M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | $28.50M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | $25.22M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | $22.12M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | $23.48M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $63.88M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $74.22M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $368.00M | Mar 3, 2026 |
| FY2024 | Dec 28, 2024 | $450.60M | Feb 25, 2025 |
| FY2023 | Dec 30, 2023 | $525.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2022 | $446.50M | Feb 28, 2023 |
| FY2021 | Jan 1, 2022 | $445.53M | Mar 1, 2022 |
| FY2020 | Jan 2, 2021 | $462.99M | Mar 2, 2021 |
| FY2019 | Dec 28, 2019 | $301.20M | Feb 25, 2020 |
| FY2018 | Dec 29, 2018 | $353.73M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 1 | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | 1 | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | 1 | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | 3 | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | 1 | Mar 1, 2022 |
| FY2016 | Dec 31, 2016 | 0 | Feb 28, 2017 |
| FY2016 | Oct 1, 2016 | 0 | Feb 28, 2017 |
| FY2016 | Jul 2, 2016 | 0 | Feb 28, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 1 | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | 1 | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | 1 | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | 3 | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | 1 | Mar 1, 2022 |
| FY2016 | Dec 31, 2016 | 0 | Feb 28, 2017 |
| FY2016 | Oct 1, 2016 | 0 | Feb 28, 2017 |
| FY2016 | Jul 2, 2016 | 0 | Feb 28, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | 33.10M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | 33.30M | Mar 3, 2026 |
| FY2024 | Dec 30, 2023 | 33.10M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 32.60M | Feb 27, 2024 |
| FY2022 | Jan 1, 2022 | 32.40M | Feb 28, 2023 |
| FY2021 | Jan 2, 2021 | 32.12M | Mar 1, 2022 |
| FY2020 | Dec 28, 2019 | 32.05M | Mar 2, 2021 |
| FY2019 | Dec 29, 2018 | 31.96M | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | 27.08M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 26.94M | Feb 27, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 3, 2026 | $12.00M | Mar 3, 2026 |
| FY2026 | Dec 28, 2024 | $11.90M | Mar 3, 2026 |
| FY2026 | Dec 30, 2023 | $11.80M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $11.70M | Feb 25, 2025 |
| FY2023 | Jan 1, 2022 | $11.60M | Feb 27, 2024 |
| FY2022 | Jan 2, 2021 | $11.60M | Feb 28, 2023 |
| FY2021 | Dec 28, 2019 | $11.53M | Mar 1, 2022 |
| FY2020 | Dec 29, 2018 | $11.00M | Mar 2, 2021 |
| FY2019 | Dec 30, 2017 | $10.26M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $10.74M | Feb 26, 2019 |